Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H28N2O5 |
| Molecular Weight | 400.4681 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1[C@H](O)C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(O)=O
InChI
InChIKey=JVHNBFFHWQQPLL-WOXROFTLSA-N
InChI=1S/C22H28N2O5/c1-28-12-3-4-13-14-5-6-24-10-11-7-18(25)21(29-2)19(22(26)27)15(11)9-17(24)20(14)23-16(13)8-12/h3-4,8,11,15,17-19,21,23,25H,5-7,9-10H2,1-2H3,(H,26,27)/t11-,15+,17-,18-,19+,21+/m1/s1
| Molecular Formula | C22H28N2O5 |
| Molecular Weight | 400.4681 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Reserpic acid, a derivative of the antihypertensive drug reserpine, can inhibit norepinephrine uptake although it is much less effective than reserpine itself. Recently was shown, that reserpic acid possessed a strong binding to the pancreatic lipase, a major target for controlling the obesity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P16233 Gene ID: 5406.0 Gene Symbol: PNLIP Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28446025 |
|||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/4030777 |
4.5 µM [Ki] | ||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/4030777 |
4.5 µM [Ki] | ||
Target ID: P16233 Gene ID: 5406.0 Gene Symbol: PNLIP Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28446025 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Medicinal plant phytochemicals and their inhibitory activities against pancreatic lipase: molecular docking combined with molecular dynamics simulation approach. | 2018-05 |
|
| Reserpic acid as an inhibitor of norepinephrine transport into chromaffin vesicle ghosts. | 1985-09-15 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4030777
Reserpic acid inhibits norepinephrine uptake although it is much less effective than reserpine itself. A Lineweaver-Burk analysis indicated that reserpic acid was a competitive inhibitor of norepinephrine transport. In the experiments: Ghosts were suspended in 1.0 ml of 0.4 M sucrose, 40 mM Mes, pH 6.8 or 1.0 ml of 0.4 M sucrose, 40 mM Hepes, pH 7.8, containing 5 mM ATP, 5 mM MgSO4, and concentration of inhibitor (reserpic acid): 3-300 uM. Chromaffin vesicles were prepared from the bovine adrenal medulla. Ghosts were prepared by resuspending the vesicles in the lysis medium.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:02:17 GMT 2025
by
admin
on
Mon Mar 31 23:02:17 GMT 2025
|
| Record UNII |
K6L9W0QP1W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46690
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | |||
|
m9533
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
65747
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | |||
|
81463
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | |||
|
K6L9W0QP1W
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | |||
|
DTXSID50232112
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY | |||
|
83-60-3
Created by
admin on Mon Mar 31 23:02:17 GMT 2025 , Edited by admin on Mon Mar 31 23:02:17 GMT 2025
|
PRIMARY |